» Articles » PMID: 37893571

Rheumatoid Arthritis Has Won the Battle but Not the War: How Many Joints Will We Save Tomorrow?

Overview
Publisher MDPI
Specialty General Medicine
Date 2023 Oct 28
PMID 37893571
Authors
Affiliations
Soon will be listed here.
Abstract

Rheumatoid arthritis refers to joint diseases of unclear etiology whose final stages can lead to unbearable pain and complete immobility of the affected joints. As one of the most widely known diseases of the joints, it serves as a study target for a large number of research groups and pharmaceutical companies. Modern treatment with anti-inflammatory drugs, including janus kinase (JAK) inhibitors, monoclonal antibodies, and botanicals (polyphenols, glycosides, alkaloids, etc.) has achieved some success and hope for improving the course of the disease. However, existing drugs against RA have a number of side effects which push researchers to elaborate on more selective and effective drug candidates. The avant-garde of research, which aims to develop treatment of rheumatoid arthritis using antisense oligonucleotides along with nonsteroidal drugs and corticosteroids against inflammation, increases the chances of success and expands the arsenal of drugs. The primary goal in the treatment of this disease is to find therapies that allow patients with rheumatoid arthritis to move their joints without pain. The main purpose of this review is to show the victories and challenges for the treatment of rheumatoid arthritis and the tortuous but promising path of research that aims to help patients experience the joy of freely moving joints without pain.

Citing Articles

A Review of the Impact of Sjögren's Syndrome and/or the Presence of Anti-Ro/SS-A Antibodies on Therapeutic Strategies for Rheumatoid Arthritis.

Horai Y, Kurushima S, Shimizu T, Nakamura H, Kawakami A J Clin Med. 2025; 14(2).

PMID: 39860574 PMC: 11766391. DOI: 10.3390/jcm14020568.


PANoptosis in autoimmune diseases interplay between apoptosis, necrosis, and pyroptosis.

Liu K, Wang M, Li D, Duc Duong N, Liu Y, Ma J Front Immunol. 2024; 15:1502855.

PMID: 39544942 PMC: 11560468. DOI: 10.3389/fimmu.2024.1502855.

References
1.
Tao W, Concepcion A, Vianen M, Marijnissen A, Lafeber F, Radstake T . Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2020; 73(2):212-222. PMC: 7898388. DOI: 10.1002/art.41516. View

2.
Romao V, Fonseca J . Etiology and Risk Factors for Rheumatoid Arthritis: A State-of-the-Art Review. Front Med (Lausanne). 2021; 8:689698. PMC: 8661097. DOI: 10.3389/fmed.2021.689698. View

3.
Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S . Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood. 2008; 113(1):214-23. DOI: 10.1182/blood-2008-07-168286. View

4.
Edrees A, Misra S, Abdou N . Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol. 2005; 23(4):469-74. View

5.
Nagy G, Roodenrijs N, Welsing P, Kedves M, Hamar A, van der Goes M . EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2020; 80(1):31-35. PMC: 7788062. DOI: 10.1136/annrheumdis-2020-217344. View